Drug Profile

Research programme: oncolytic virus therapies - VCN Biosciences

Alternative Names: VCN-X; VCN-X and Albumin Shield

Latest Information Update: 29 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator VCN Biosciences
Developer Theriva Biologics
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
Mechanism of Action Cell death stimulants; Hyaluronidase replacements; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

06 Apr 2026 Preclinical trials in Solid tumours in Spain (IV) prior to April 2026 (Theriva Biologics pipeline, April 2026)
12 Oct 2022 Synthetic Biologics is now called Theriva Biologics
11 Mar 2022 VCN Biosciences has been acquired by Synthetic Biologics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com